key: cord-1007355-ktl0swc6
authors: Hassanipour, Soheil; Arab-Zozani, Morteza; Amani, Bahman; Heidarzad, Forough; Fathalipour, Mohammad; Martinez-de-Hoyo, Rudolph
title: Addendum: The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials
date: 2022-02-01
journal: Sci Rep
DOI: 10.1038/s41598-022-05835-2
sha: 8802994f08ace6e421fcef5f474f137e6eab7820
doc_id: 1007355
cord_uid: ktl0swc6

nan

Addendum to: Scientific Reports https:// doi. org/ 10. 1038/ s41598-021-90551-6, published online 26 May 2021

In the original version of this Article we included the data reported in a preprint by Dabbous et al. entitled "Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial", which was later published 1 . After publication of our Article it was brought to our attention that Dabbous et al. ' paper had subsequently been retracted 2 . We have therefore repeated sub-analyses in which this study was originally included to establish the effect of the removal of this data from the review. 

The result of the updated meta-analysis show that viral clearance 7, 10, and 14 days after hospitalization is not statistically different between the Favipiravir and control groups (RR = 1.13, 95% CI: 0.83-1.53; P = 0.425, I2 = 66.0%, P = 0.019 for 7 days; RR = 1.04, 95% CI: 0.93-1.16; P = 0.454, I2 = 0.0%, P = 0.973 for 10 days; RR = 1.11, 95% CI: 0.91-1.36; P = 0.264, I2 = 60.9%, P = 0.077 for 14 days) (Fig. 1) .

Based on the updated meta-analysis, the mortality rate in the Favipiravir group was approximately 23% lower than in the control group, but this finding is not statistically significant (RR = 0.77, 95% CI: 0.26-2.19; P = 0.625, I2 = 0.0%, P = 0.585) (Fig. 2) .

License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/. © The Author(s) 2022 

RETRACTED ARTICLE: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial

Retraction Note: Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial